This Month in Adult Urology

A common lament of clinicians is the lack of good biomarkers to predict which men may have clinically significant prostate cancer to better determine those who may benefit from a prostate biopsy. Commercially available tests exist but their use has been restricted in part because of their expense. Two studies in this issue of The Journal specifically explore the cost-effectiveness of some of the available biomarkers and reach similar conclusions.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: This Month in Adult Urology Source Type: research